p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl)
about
The proximal signaling network of the BCR-ABL1 oncogene shows a modular organizationThe unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.The role of protein tyrosine phosphatase 1B in Ras signalingPten dose dictates cancer progression in the prostateThe non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseModulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modificationsFunctional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinaseTransforming pathways activated by the v-Abl tyrosine kinasePhosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signalingPhosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradationc-Abl phosphorylates Dok1 to promote filopodia during cell spreadingmRNA expression of DOK1-6 in human breast cancerDownstream of tyrosine kinase/docking protein 6, as a novel substrate of tropomyosin-related kinase C receptor, is involved in neurotrophin 3-mediated neurite outgrowth in mouse cortex neurons.Rasal2 deficiency reduces adipogenesis and occurrence of obesity-related disorders.DOK4 and DOK5: new Dok-related genes expressed in human T cells.Identification of DOK genes as lung tumor suppressors.Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.PML targeting eradicates quiescent leukaemia-initiating cells.BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformationHigh affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.The inositol 5-phosphatase SHIP-1 and adaptors Dok-1 and 2 play central roles in CD4-mediated inhibitory signaling.Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sitesPhosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation.Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice.Role of Dok-1 and Dok-2 in leukemia suppression.Advances in targeting IKK and IKK-related kinases for cancer therapyIn Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells.IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.Grb10 is involved in BCR-ABL-positive leukemia in mice.Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells.A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia.
P2860
Q24294830-75234459-4567-46E7-90FE-136587912D70Q24297359-3491C3F8-6FF4-4D6B-92ED-9BE972D86A88Q24522667-6D245DFB-5389-4250-96BB-3205B522D1E3Q24622106-FDF0BFFA-A5B8-4FE3-BF1B-9EE04CAF2911Q24791909-FDD03A15-FA68-44E7-B94D-C4EE3E92C87DQ26749343-A74CAB34-CFB2-4476-AF43-CB8C0860C66EQ27015807-EF098804-6934-477C-A5FA-C3183494C1CBQ28188565-368AA413-8E8F-466D-9510-309398156555Q28217156-B0836C73-8D07-4167-B7FC-8BE2EA2CC223Q28217308-70603E8F-BB32-42A1-BD42-5CDFA516FD04Q28256858-EDE338B6-0C4E-4FFC-AAC5-4A159B0C7A6DQ28510526-57B418C8-7D03-4CA5-A13F-5414CAE06AF9Q33585060-B127F1CE-C4C7-4267-B3A6-211717D8F3FFQ33611140-A8DA75C6-C018-45CF-B72D-05140FA51F3AQ33726373-2DFD683E-ADC0-4DDD-B816-DDD6281C8E4EQ34178678-83DB4FAB-32EA-49E3-B5F7-E741F503383BQ34207099-23250039-6754-4FC0-8345-713A6CCE6473Q34258443-091470A7-6E1E-4143-905F-0E9AD0E69AF6Q34355754-B83EC035-D88A-4F70-BC03-5BABF56F383DQ34591761-495A4F82-0FDB-40A8-ADC6-C27B904A8E13Q35093544-DAAD5482-7563-4B09-8240-5A3651135BCBQ35096609-665CE9DE-F7B7-495F-B69D-F8B53DF33122Q35104353-1D42A7E7-16F2-4241-8A55-C315CF54CEE8Q35165290-2232917B-B294-42B1-ACA4-9F43726C4EA7Q35857125-E544EECE-8F9F-494B-A29B-D6AA88D3D69BQ36174930-C19C2485-AF0E-47C9-9BCA-C34DE207FF8BQ36228047-C6589DB0-4AE8-4FC3-B977-21AEB7428635Q36323631-2A0E397A-8487-4F2B-BB7D-FA9132BBCBE2Q36369432-AD556148-D77D-432A-81D6-824AE7DBAB8BQ36369746-D8264AA9-455C-4874-9254-AF8652FB494CQ36399814-E94B958A-6A2B-4BEF-83EB-D3EC2274851EQ37036746-A0CD8C7C-5519-4640-A29A-C19E28AC83F9Q37432558-C71BE1CA-D19A-4E35-A568-81355535EEFCQ37713955-F03624C0-F953-475B-97FE-ED9871E5A715Q38953915-2DF66817-D4D2-4023-986B-6833C78865F3Q39267923-9BA5AE40-3045-402C-906C-A6B2418BC230Q39442006-3FEE96B2-9854-4FD3-8063-929A7A4A54CCQ39968515-32394AF1-30AE-4727-BF3B-F537D40461C2Q40350288-B5A572CC-8DA4-4208-8A65-3EBC8AD893FDQ40476627-E2716D92-DC9B-4A70-BE9A-C17D2BE25FAE
P2860
p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl)
description
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im August 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2001/08/06)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/08/06)
@nl
наукова стаття, опублікована в серпні 2001
@uk
مقالة علمية (نشرت في 6-8-2001)
@ar
name
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@ast
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@en
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@nl
type
label
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@ast
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@en
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@nl
prefLabel
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@ast
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@en
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@nl
P2093
P2860
P3181
P356
P1476
p62(dok), a negative regulator ...... eukemogenesis by p210(bcr-abl)
@en
P2093
A. Di Cristofano
B. Clarkson
F. G. Karnell
L. Van Aelst
P. P. Pandolfi
W. S. Pear
P2860
P304
P3181
P356
10.1084/JEM.194.3.275
P407
P577
2001-08-06T00:00:00Z